论文部分内容阅读
选择正接受二甲双胍单药治疗血糖控制差的2型糖尿病人83例(HbA1c>7.1%),并分为三组,29例改用单用诺和龙治疗,27例继续单用二甲双胍治疗,27例采用诺和龙加二甲双胍联合治疗为期3个月。结果,二甲双胍单药组和诺和龙单药组的HbA1c水平分别由8.6%降至8.3%和8.2%,而诺和龙联合二甲双胍组则由8.3%降至6.9%(P<0.001),联合用药组中59%的患者HbA1c水平最后降至7.1%以下,而二甲双胍和诺和龙单药组仅分别有20%和22%的患者降至7.1%以下,与基线比较,联合用药可使FPG下降2.2mmol/L,表面诺和龙与二甲双胍联用的降糖效果优于诺和龙和二甲双胍单独用药。
A total of 83 type 2 diabetic patients (HbA1c> 7.1%) with poor glycemic control who were receiving metformin monotherapy were enrolled and divided into three groups: 29 patients switched to noradrenaline alone, 27 patients continued to receive metformin alone, 27 Cases with Novolin and metformin combination therapy for a period of 3 months. As a result, HbA1c levels decreased from 8.6% to 8.3% and 8.2% in metformin monotherapy and norepinephrine monotherapy, respectively, and decreased from 8.3% to 6.9% in combination with norfloxacin and metformin (P <0.001) HbA1c levels dropped to below 7.1% in 59% of the patients in the medication group, whereas those in the metformin and nocodazole groups dropped to 7.1% or less in only 20% and 22%, respectively Decreased by 2.2mmol / L, the combination of Novo Nordisk and Metformin had better hypoglycemic effect than Novozymes and Metformin alone.